Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

NCT02550080 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

3130

Enrollment

OTHER

Sponsor class

Conditions

Allergic Cutaneous Vasculitis
Urticaria
Psoriasis
Acne
Bullous Skin Diseases
Sterile Pustulosis
Leprosy
Pneumocystis Pneumonia

Interventions

DRUG: Dapsone
GENETIC: HLA-B*1301

Sponsor

Shandong Provincial Institute of Dermatology and Venereology

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]